Why Adagio Therapeutics Stock Dived by 13% Today
One of the more disappointing biotech stocks of recent weeks, Adagio Therapeutics (NASDAQ: ADGI), was hammered once again on Wednesday, with its share price tumbling by over 13%. This followed a fresh analyst downgrade of the stock, one of several that have occurred lately.
The latest to downgrade Adagio stock is Jefferies' Michael Yee, who has changed his recommendation from buy to hold, at a price target of $10 per share.
Source Fool.com
